Bardoxolone Blow-Up: Reata/Abbott CKD Drug Halted In Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Reata has terminated the Phase III BEACON trial for its chronic kidney disease hopeful bardoxolone methyl, partnered with Abbott, due to safety concerns.
You may also be interested in...
Reata Expands Options For Bardoxolone With New CKD Data
Once suspended due to safety issues, bardoxolone now has completed a Phase II study that showed kidney function benefit in four rare types of CKD. A pivotal study is underway, with another planned and more possible.
Outlook For Reata's Bardoxolone Improves With Phase II Updates
Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).
An NME Surge After The Patent Cliff? Reinvention Of R&D Starts Paying Off In 2013 New Product Candidates
With more than 40 novel agents already pending at FDA, 2013 looks like a good bet to repeat the strong NME and novel biologic approval counts of 2012 and 2011. Big pharma and big markets dominate the 2013 slate so far, especially with diabetes, respiratory and central nervous system candidates.